Aphria Inc. Receives EU GMP Certification for Aphria One Facility

Published: January 23, 2020

Aphria Inc. Receives EU GMP Certification for Aphria One Facility

Aphria Inc. has received its European Union Good Manufacturing Practices (“EU GMP”) certification as an active substance manufacturer in accordance with Art.111 of Directive 2001/83 EC from the Malta Medicines Authority (“MMA”) at the Company’s Aphria One facility in Leamington, Ontario.  This marks Aphria’s second EU GMP certified facility, following the previously announced certification at the Company’s subsidiary, ARA – Avanti Rx Analytics (“Avanti”).

“We are pleased to receive EU GMP certification for our Aphria One facility which strengthens our international export capabilities,” said Irwin D. Simon, Chief Executive Officer. “Looking ahead, we are excited by the momentum and expect to see acceleration in terms of both sales and profitability in the second half of fiscal 2020. We continue to believe the opportunities for long-term shareholder value creation are very strong in Canada and internationally.”

As with the Company’s EU GMP certification of Avanti, Aphria selected the MMA to perform the EU GMP audit as the criteria and certification thresholds established by the MMA are among the most stringent and demanding in the EU. The certification will allow the Company’s Aphria One facility to be a supplier of bulk dried flower for medicinal use worldwide to other EU GMP certified facilities licensed to further process or package bulk dried flower into finished cannabis product for sale in permitted jurisdictions.

Recent News

View All News Items

Latest Article

Legalization 2.0: IP and Regulatory Considerations for Edibles, Extracts and Topicals

Legalization 2.0: IP and Regulatory Considerations for Edibles, Extracts and Topicals

The legalization of cannabis edibles, extracts and topicals will expand the cannabis market and create new opportunities for producers, innovators and investors. According to a recent report from Deloitte, the Canadian market for these new cannabis products is expected to be worth $2.7 billion annually, with edibles accounting for more than half ($1.6 billion).

 

Read Article